US · TMO · MEDICAL - DIAGNOSTICS & RESEARCH
Thermo Fisher Scientific Inc. (TMO) intrinsic value and stock valuation
$669.54as of 2026-11-21 · Mkt cap 220.74B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Thermo Fisher Scientific Inc. DCF and intrinsic value
InvestorsCraft values TMO with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from TMO’s statements →
Thermo Fisher Scientific Inc. Graham Number
Graham Number: $239.59d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Merck & Co., Inc. (MRK) $133.72
- Novartis AG (NVS) $150.47
- AstraZeneca PLC (AZN) $174.35
- Amgen Inc. (AMGN) $435.64
- Novo Nordisk A/S (NVO) $37.82
- Abbott Laboratories (ABT) $103.00
- Danaher Corporation (DHR) $220.36
- Intuitive Surgical, Inc. (ISRG) $399.05
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $44.6B | $42.9B | $42.9B | $44.9B | $39.2B |
| Operating income | $8.11B | $7.66B | $7.45B | $8.53B | $10.3B |
| Net income | $6.74B | $6.34B | $6B | $6.95B | $7.73B |
| EPSd | $17.9M | $16.5M | $15.5M | $17.6M | $19.5M |
| Operating cash flow | $7.82B | $8.67B | $8.41B | $9.15B | $9.54B |
| Capital expenditure | -$-1.53B | -$-1.4B | -$-1.48B | -$-2.24B | -$-2.52B |
| Free cash flow | $6.29B | $7.27B | $6.93B | $6.91B | $7.02B |
| Total assets | $110.3B | $97.3B | $98.7B | $97.2B | $95.1B |
| Total debt | $39.4B | $32.8B | $36.4B | $36.1B | $36.3B |
| Net debt | $29.5B | $28.8B | $28.3B | $27.5B | $31.9B |
| Total equity | $53.5B | $49.7B | $46.8B | $44.1B | $41B |
| Cash and short-term investments | $10.1B | $5.58B | $8.08B | $8.52B | $4.48B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $44.6B | $42.9B | $42.9B | $44.9B | $39.2B |
| Cost of revenue | $27.8B | $25.2B | $25.7B | $25.9B | $19.6B |
| Gross profit | $16.8B | $17.7B | $17.2B | $19B | $19.6B |
| Research and development expenses | $1.4B | $1.39B | $1.34B | $1.47B | $1.41B |
| Selling, general and administrative expenses | $7.27B | $8.68B | $8.41B | $9.02B | $7.91B |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $8.67B | $10.1B | $9.75B | $10.5B | $9.32B |
| Cost and expenses | $36.4B | $35.2B | $35.4B | $36.4B | $28.9B |
| Interest income | $993M | $1.08B | $879M | $272M | $43M |
| Interest expense | $1.42B | $1.65B | $1.49B | $726M | $536M |
| Depreciation and amortization | $2.78B | $3.11B | $3.41B | $3.38B | $2.59B |
| Ebitda | $11.5B | $11.8B | $11.2B | $11.9B | $12B |
| Operating income | $8.11B | $7.66B | $7.45B | $8.53B | $10.3B |
| Total other income/expenses, net | -$-842M | -$-667M | -$-1.21B | -$-862M | -$-1.48B |
| Income before tax | $7.27B | $7B | $6.24B | $7.66B | $8.84B |
| Income tax expense | $547M | $657M | $284M | $703M | $1.11B |
| Net income | $6.74B | $6.34B | $6B | $6.95B | $7.73B |
| Weighted average shares outstanding | $376M | $382M | $386M | $392M | $394M |
| Weighted average diluted shares outstanding | $377M | $383M | $388M | $394M | $397M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $10.1B | $5.58B | $8.08B | $8.52B | $4.48B |
| Net receivables | $10.6B | $9.63B | $9.66B | $9.43B | $8.95B |
| Inventory | $5.43B | $4.98B | $5.09B | $5.63B | $5.05B |
| Total current assets | $28.7B | $22.1B | $24.6B | $25.2B | $20.1B |
| Property, plant and equipment, net | $10.6B | $10.8B | $11B | $10.9B | $9.86B |
| Goodwill and intangible assets | $65.2B | $61.4B | $60.7B | $58.7B | $62.1B |
| Long-term investments | $0.00 | $560M | $59M | $155M | $73M |
| Total non-current assets | $81.6B | $75.2B | $74.1B | $71.9B | $75B |
| Total assets | $110.3B | $97.3B | $98.7B | $97.2B | $95.1B |
| Accounts payable | $3.62B | $3.08B | $2.87B | $3.38B | $2.87B |
| Short-term debt | $3.53B | $2.48B | $3.87B | $5.85B | $2.8B |
| Deferred revenue | $2.71B | $2.85B | $2.69B | $2.6B | $2.66B |
| Total current liabilities | $15.2B | $13.3B | $14B | $17B | $13.4B |
| Long-term debt | $35.9B | $30.3B | $32.6B | $30.2B | $33.5B |
| Deferred revenue, non-current | $0.00 | $1.14B | $1.5B | $1.18B | $1.24B |
| Total non-current liabilities | $41.6B | $34.3B | $37.9B | $36B | $40.7B |
| Capital lease obligations | $0.00 | $1.24B | $1.24B | $1.31B | $1.39B |
| Total liabilities | $56.8B | $47.7B | $51.9B | $53B | $54.1B |
| Common stock | $445M | $444M | $442M | $441M | $439M |
| Retained earnings | $59.2B | $53.1B | $47.4B | $41.9B | $35.4B |
| Accumulated other comprehensive income (loss) | -$-2.45B | -$-2.7B | -$-3.22B | -$-3.1B | -$-2.33B |
| Total equity | $53.5B | $49.7B | $46.8B | $44.1B | $41B |
| Total investments | $253M | $2.12B | $59M | $155M | $73M |
| Total debt | $39.4B | $32.8B | $36.4B | $36.1B | $36.3B |
| Net debt | $29.5B | $28.8B | $28.3B | $27.5B | $31.9B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $6.72B | $6.34B | $6B | $6.96B | $7.73B |
| Depreciation and amortization | $2.78B | $3.11B | $3.41B | $3.38B | $2.59B |
| Stock-based compensation | $310M | $301M | $278M | $307M | $230M |
| Change in working capital | -$-1.77B | -$-334M | -$-537M | -$-1.05B | -$-1.56B |
| Accounts receivable | -$-426M | -$-171M | $209M | -$-430M | -$-204M |
| Inventory | -$-74M | -$-27M | $598M | -$-825M | -$-1.07B |
| Accounts payable | $421M | $212M | -$-500M | $648M | $479M |
| Net cash provided by operating activities | $7.82B | $8.67B | $8.41B | $9.15B | $9.54B |
| Investments in property, plant and equipment | -$-1.53B | -$-1.4B | -$-1.48B | -$-2.24B | -$-2.52B |
| Acquisitions, net | -$-4.04B | -$-3.13B | -$-3.66B | -$-39M | -$-19.4B |
| Net cash used for investing activities | -$-4.05B | -$-5.84B | -$-5.14B | -$-2.16B | -$-21.93B |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-3B | -$-4B | -$-3B | -$-3B | -$-2B |
| Dividends paid | -$-636M | -$-583M | -$-523M | -$-455M | -$-395M |
| Net cash used for financing activities | $1.8B | -$-6.79B | -$-3.62B | -$-2.81B | $6.58B |
| Net change in cash | $5.84B | -$-4.06B | -$-440M | $4.05B | -$-5.85B |
| Cash at end of period | $9.88B | $4.04B | $8.1B | $8.54B | $4.49B |
| Operating cash flow | $7.82B | $8.67B | $8.41B | $9.15B | $9.54B |
| Capital expenditure | -$-1.53B | -$-1.4B | -$-1.48B | -$-2.24B | -$-2.52B |
| Free cash flow | $6.29B | $7.27B | $6.93B | $6.91B | $7.02B |
Line items
Line items
Line items
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.
- CEO
- Marc N. Casper
- Employees
- 125K
- Beta
- 0.87
Included in
Explore
Frequently asked questions
What is the intrinsic value of Thermo Fisher Scientific Inc. (TMO)?
Thermo Fisher Scientific Inc. (TMO) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is TMO undervalued?
TMO trades at a price of $669.54 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.